Table A1.
Baseline characteristics of patients that received chemotherapy.
| Trial Name | DANUBE | KEYNOTE-361 | IMvigor130 |
|---|---|---|---|
| Durva + Treme vs. Durva vs. CTX | Pembro vs. Prmbro + CTX vs. CTX | Atezo vs. Atezo + CTX vs. CTX | |
| patient number of chemotherapy | 344 | 352 | 400 |
| patient characteristics of chemotherapy | |||
| median age | 68 | 69 | 67 |
| male (%) | 80% | 74.40% | 75% |
| site of metastatic disease | |||
| lymph node only | 22% | 26.70% | 17% |
| visceral metastases | 77% | 71.60% | 60% |
| liver metastases | unknown | 21.00% | 13% |
| ECOG status | |||
| 0 | 55% | 47.70% | 43% |
| 1 | 45% | 46.00% | 47% |
| 2 | <1% | 6.30% | 10% |
| choice of chemotherapy | |||
| Cisplatin | 56% | 45.50% | 66% |
| Carboplatin | 44% | 54.50% | 34% |
| PD-L1 expression 1 | high: 60% | PD-L1 CPS ≥ 10:45.2% | IC2/3:23% |
| low: 40% | IC1:45% | ||
1 PD-L1 expression, DANUBE—High PD-L1 expression was defined as at least 25% of tumor cells with membrane staining or at least 25% of immune cells staining for PD-L1 at any intensity if more than 1% of the tumor area contained immune cells or 100% of immune cells staining for PD-L1 at any intensity if 1% of the tumor area contained immune cells. KEYNOTE-361—combined positive score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. The specimen should be considered to have PD-L1 expression if CPS ≥ 1. IMvigor130—IC0: Tumor-infiltrating immune cells (IC) < 1%, IC1:IC ≥ 1% and <5%, IC2/3:IC ≥ 5%.